Valuation : Penumbra, Inc.

Market Cap 12.69B 10.92B 10.27B 9.39B 17.56B 1,198B 17.6B 121B 47.11B 615B 47.65B 46.61B 1,980B P/E 2026 *
73.1x
P/E 2027 * 52.6x
Enterprise Value 12.24B 10.54B 9.91B 9.05B 16.94B 1,156B 16.98B 117B 45.45B 593B 45.97B 44.97B 1,911B EV / Sales 2026 *
7.69x
EV / Sales 2027 * 6.65x
Free-Float
97.1%
Yield 2026 *
-
Yield 2027 * -
1 day+0.32%
1 week+0.15%
Current month-0.29%
1 month-0.63%
3 months+0.48%
6 months-5.14%
Current year+3.62%
1 week 320.97
Extreme 320.97
325
1 month 320.83
Extreme 320.83
328.6
Current year 290
Extreme 290
362.41
1 year 221.26
Extreme 221.26
362.41
3 years 148
Extreme 148
362.41
5 years 114.86
Extreme 114.865
362.41
10 years 56.05
Extreme 56.05
362.41
Manager TitleAgeSince
Chief Executive Officer 64 2004-06-20
President 41 2025-08-31
Director of Finance/CFO 54 2019-12-01
Director TitleAgeSince
Chairman 64 2014-12-31
Chairman 64 2004-12-31
Director/Board Member 59 2015-03-31
Date Insider Type Main position Quantity % Market Cap. Importance
8/17/26 Free

Chairperson

3,060 0.0078%
5/19/26 Don

Chief Executive Officer

-77,000 0.1958%
4/2/26 Sell

Director

100 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
+0.32%+0.15%+15.18%+21.98% 12.69B
-0.98%-2.26%+15.69%+25.94% 6.88B
-2.33%+15.85% - - 6.54B
-2.41%-7.59%+30.36%+20.60% 5.99B
+3.02%+1.31%-17.27%+53.59% 5.21B
+0.51%-1.90%-29.86%-22.51% 3.83B
+1.70%+0.67%+49.75%-19.52% 2.09B
-2.02%-3.00%-7.32%+130.04% 1.72B
+2.63%-1.57%+53.11%-14.27% 1.64B
-1.26%+1.19%-3.23%+18.55% 1.38B
Average -0.08%+0.53%+11.82%+23.82% 4.8B
Weighted average by Cap. -0.25%+1.05%+10.91%+23.16%

Financials

2026 *2027 *
Net sales 1.59B 1.37B 1.29B 1.18B 2.2B 150B 2.21B 15.24B 5.91B 77.17B 5.98B 5.85B 249B 1.8B 1.55B 1.46B 1.33B 2.49B 170B 2.5B 17.22B 6.68B 87.18B 6.76B 6.61B 281B
Net income 176M 152M 143M 130M 244M 16.66B 245M 1.69B 655M 8.55B 663M 648M 27.53B 242M 209M 196M 179M 335M 22.88B 336M 2.32B 900M 11.74B 910M 890M 37.82B
Net Debt -447M -385M -362M -331M -618M -42.2B -620M -4.28B -1.66B -21.65B -1.68B -1.64B -69.76B -729M -627M -590M -539M -1.01B -68.8B -1.01B -6.97B -2.71B -35.3B -2.74B -2.68B -114B
Logo Penumbra, Inc.
Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada, Australia and Singapore, as well as through distributors in select international markets.
Employees
4,700
Date Price Change Volume
26-09-04 US$322.17 +0.32% 174,065
26-09-03 US$321.14 -0.51% 313,873
26-09-02 US$322.80 +0.07% 220,280
26-09-01 US$322.58 -0.16% 150,763
26-08-31 US$323.10 +0.44% 477,149
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
16
Last Close Price
322.17USD
Average target price
361.83USD
Spread / Average Target
+12.31%

Quarterly revenue - Rate of surprise